Orbis Research Present’s Gouty Arthritis (Gout)-API Insights, 2017 Market Report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage of a majority of the APIs and intermediates produced in the world currently. The USFDA and EMA have strict guidelines for API manufacturing ‘Process Validation: General Principles and Practices’. While countries such as Japan and Singapore are signatories to the ICH Q7 regulation, India and China follow their national GMP guidelines. The efficiency and expertise of Asian contract manufacturers have positioned them in a very strategic space in the global pharmaceutical supply chain, with a vast majority of the APIs and intermediates being sourced from markets such as India and China.
Get a PDF Sample of Gouty Arthritis (Gout)-API Insights, 2017 Report at: http://www.orbisresearch.com/contacts/request-sample/210923
Gouty Arthritis (Gout) -API Insights, 2017 Report describes the current therapeutics that are propelling the pharmaceutical markets worldwide. The report gives the clear idea on the United States Drug Master File (USDMF) and Europe DMF filed by worldwide countries related to the Gouty Arthritis (Gout). It also provides the India and China API Manufactures who are driving the current API Market. The report also highlights the patent and patent exclusivity information. The research analysis also presents the global sales data till 2016.
The report is built using data and information sourced from proprietary databases, primary and secondary…